

a⁶ 18. (Amended) A pharmaceutical composition which comprises an inhibitor as defined in claim 14 [any one of claims 14-17] or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

19. (Amended) A method of mapping nuclear receptor interaction domains in nuclear proteins in which the method comprises analysis of the sequence of a nuclear protein for the presence of signature motifs as defined in any one of claims 1, 2 and 5 [1-6] in order to identify an interaction domain or a potential interaction domain.

Please add the following new claims 20-22:

a⁷ --20. A pharmaceutical composition which comprises an inhibitor as defined in claim 15 or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

21. A pharmaceutical composition which comprises an inhibitor as defined in claim 16 or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.

22. A pharmaceutical composition which comprises an inhibitor as defined in claim 17 or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable diluent or carrier.--

REMARKS

The above amendments have been made for the purpose of correcting multiple dependencies which were improper under US practice in the application as filed, and for minor reformatting of claim 14. In particular it is noted that new dependent claims 20-22 are


identical to original claim 18, except that each of pharmaceutical composition claims 18, 20, 21 and 22 is dependent on only a single multiple dependent claim. Claims 1-22 are in this application following entry of the above amendments.

No new matter has been added. Accordingly, entry of these amendments is believed to be in order, and is respectfully requested before examination and issuance of a first Action on the merits.

Respectfully Submitted,

PILLSBURY MADISON & SUTRO LLP
Intellectual Property Group

By:


Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 861-3027
Fax No.: (202) 822-0944

DJB:
1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918